Prenatal diagnosis of HNF1B-associated renal cysts: Is there a need to differentiate intragenic variants from 17q12 microdeletion syndrome? by Vasileiou, Georgia et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Prenatal diagnosis of HNF1B-associated renal cysts: Is there a need to
differentiate intragenic variants from 17q12 microdeletion syndrome?
Vasileiou, Georgia ; Hoyer, Juliane ; Thiel, Christian T ; Schaefer, Jan ; Zapke, Maren ; Krumbiegel,
Mandy ; Kraus, Cornelia ; Zweier, Markus ; Uebe, Steffen ; Ekici, Arif B ; Schneider, Michael ;
Wiesener, Michael ; Rauch, Anita ; Faschingbauer, Florian ; Reis, André ; Zweier, Christiane ; Popp,
Bernt
Abstract: OBJECTIVE 17q12 microdeletions containing HNF1B and intragenic variants within this
gene are associated with variable developmental, endocrine, and renal anomalies, often already noted
prenatally as hyperechogenic/cystic kidneys. Here, we describe prenatal and postnatal phenotypes of
seven individuals with HNF1B aberrations and compare their clinical and genetic data to those of previous
studies. METHODS Prenatal sequencing and postnatal chromosomal microarray analysis were performed
in seven individuals with renal and/or neurodevelopmental phenotypes. We evaluated HNF1B-related
clinical features from 82 studies and reclassified 192 reported intragenic HNF1B variants. RESULTS In
a prenatal case, we identified a novel in-frame deletion p.(Gly239del) within the HNF1B DNA-binding
domain, a mutational hot spot as demonstrated by spatial clustering analysis and high computational
prediction scores. The six postnatally diagnosed individuals harbored 17q12 microdeletions. Literature
screening revealed variable reporting of HNF1B-associated clinical traits. Overall, both mutation groups
showed a high phenotypic heterogeneity. The reclassification of all previously reported intragenic HNF1B
variants provided an up-to-date overview of the mutational spectrum. CONCLUSIONS We highlight the
value of prenatal HNF1B screening in renal developmental diseases. Standardized clinical reporting
and systematic classification of HNF1B variants are necessary for a more accurate risk quantification of
prenatal and postnatal clinical features, improving genetic counseling and prenatal decision making.
DOI: https://doi.org/10.1002/pd.5556
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-179361
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Vasileiou, Georgia; Hoyer, Juliane; Thiel, Christian T; Schaefer, Jan; Zapke, Maren; Krumbiegel, Mandy;
Kraus, Cornelia; Zweier, Markus; Uebe, Steffen; Ekici, Arif B; Schneider, Michael; Wiesener, Michael;
Rauch, Anita; Faschingbauer, Florian; Reis, André; Zweier, Christiane; Popp, Bernt (2019). Prenatal
diagnosis of HNF1B-associated renal cysts: Is there a need to differentiate intragenic variants from 17q12
microdeletion syndrome? Prenatal Diagnosis, 39(12):1136-1147.
DOI: https://doi.org/10.1002/pd.5556
2
OR I G I N A L A R T I C L E
Prenatal diagnosis of HNF1B-associated renal cysts: Is there a
need to differentiate intragenic variants from 17q12
microdeletion syndrome?
Georgia Vasileiou1 | Juliane Hoyer1 | Christian T. Thiel1 | Jan Schaefer2 |
Maren Zapke2 | Mandy Krumbiegel1 | Cornelia Kraus1 | Markus Zweier3 |
Steffen Uebe1 | Arif B. Ekici1 | Michael Schneider4 | Michael Wiesener5 |
Anita Rauch3 | Florian Faschingbauer4 | André Reis1 | Christiane Zweier1 |
Bernt Popp1,6
1Institute of Human Genetics, Friedrich-
Alexander-Universität Erlangen-Nürnberg
(FAU), Erlangen, Germany
2Department of Pediatrics and Adolescent
Medicine, University Hospital of Erlangen-
Nürnberg (FAU), Erlangen, Germany
3Institute of Medical Genetics, University of
Zurich, Schlieren-Zurich, Switzerland
4Department of Obstetrics and Gynecology,
Erlangen University Hospital, Erlangen,
Germany
5Department of Nephrology and
Hypertension, Friedrich-Alexander-Universität
Erlangen-Nürnberg (FAU), Erlangen, Germany
6Institute of Human Genetics, University of
Leipzig Hospitals and Clinics, Leipzig, Germany
Correspondence
Bernt Popp, Institute of Human Genetics,
University of Leipzig Hospitals and Clinics,
Leipzig 04103, Germany.
Email: bernt.popp@medizin.uni-leipzig.de
Georgia Vasileiou, Institute of Human
Genetics, Friedrich-Alexander-Universität
Erlangen-Nürnberg (FAU), Schwabachanlage
10, Erlangen 91054, Germany.
Email: georgia.vasileiou@uk-erlangen.de
Funding information
IZKF Erlangen, Grant/Award Number: E16;
Bundesministerium für Bildung und Forschung,
Grant/Award Numbers: 01GM1520A,
01GS08160
Abstract
Objective: 17q12 microdeletions containing HNF1B and intragenic variants within
this gene are associated with variable developmental, endocrine, and renal anomalies,
often already noted prenatally as hyperechogenic/cystic kidneys. Here, we describe
prenatal and postnatal phenotypes of seven individuals with HNF1B aberrations and
compare their clinical and genetic data to those of previous studies.
Methods: Prenatal sequencing and postnatal chromosomal microarray analysis were
performed in seven individuals with renal and/or neurodevelopmental phenotypes.
We evaluated HNF1B-related clinical features from 82 studies and reclassified
192 reported intragenic HNF1B variants.
Results: In a prenatal case, we identified a novel in-frame deletion p.(Gly239del)
within the HNF1B DNA-binding domain, a mutational hot spot as demonstrated by
spatial clustering analysis and high computational prediction scores. The six postna-
tally diagnosed individuals harbored 17q12 microdeletions. Literature screening rev-
ealed variable reporting of HNF1B-associated clinical traits. Overall, both mutation
groups showed a high phenotypic heterogeneity. The reclassification of all previously
reported intragenic HNF1B variants provided an up-to-date overview of the muta-
tional spectrum.
Conclusions: We highlight the value of prenatal HNF1B screening in renal develop-
mental diseases. Standardized clinical reporting and systematic classification of
HNF1B variants are necessary for a more accurate risk quantification of prenatal and
postnatal clinical features, improving genetic counseling and prenatal decision
making.
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1 | INTRODUCTION
The HNF1B (hepatocyte nuclear factor-1-beta, MIM *189907; also
known as transcription factor-2 [TCF2]) protein is a transcription fac-
tor that, together with its dimerization partner HNF1A, belongs to the
homeodomain-containing superfamily.1 HNF1B is highly expressed in
numerous fetal/adult tissues, where it mediates tissue-specific gene
expression, development, and function.2,3 It has a prominent role in
fetal renal development, including regulation of organization and dif-
ferentiation of renal epithelium,1,4,5 urogenital formation,4,6 and tubu-
lar development in the nephron.1
Genetic variants affecting HNF1B are associated with multiple
phenotypes.7-11 Aberrations of HNF1B were initially described as
causative for maturity-onset diabetes of the young type 5 (MODY5;
MIM #137920).1,8,11-13 Furthermore, HNF1B variants have been
shown to be causal for the renal cysts and diabetes syndrome (RCAD;
MIM #137920),14 renal hypodysplasia (RHD),15 familial
glomerulocystic kidney disease (GCKD),16 autosomal dominant
tubulointerstitial kidney disease (ADTKD, also “medullary cystic kid-
ney disease” [MCKD] or “juvenile hyperuricemic nephropathy”
[FJHN]),17,18 and congenital anomalies of kidney and urinary tract
(CAKUT).8,11,15,16,19 The latter is a frequent cause of severe fetal renal
anomalies often leading to termination of pregnancy (TOP), neonatal
death, and chronic renal disease in children.19-21
Apart from diabetes mellitus and the highly heterogeneous renal
phenotype, with the most common manifestations being hyper-
echogenic kidneys prenatally22 and renal cysts postnatally,11 HNF1B
aberrations have been associated with several other clinical anomalies.
These include agenesis or hypoplasia of the pancreas,8,19 impaired
liver function,23 urogenital anomalies,24 electrolyte abnormalities,17,25
and diaphragmatic hernia.26
HNF1B pathogenic variants include intragenic mutations such as
single-nucleotide variants (SNVs), small insertions or deletions of
bases (indels), and small copy number variants (CNVs) affecting only
parts of the gene as well as larger CNVs encompassing the entire
HNF1B.7 SNVs/indels described to date include nonsense, frameshift,
splice-site, and missense variants. The latter are mainly distributed
within exons 2 to 4, which code for the DNA-binding domain.8,19,22,27
All described HNF1B whole gene deletions so far correspond to chro-
mosome 17q12 microdeletions spanning 1.3 to 1.8 Mb on average
and including neighboring genes.10,28,29 Both intragenic variants and
genomic rearrangements contribute almost equally to the HNF1B-
associated phenotype.11
Importantly, numerous studies reported neurodevelopmental dis-
orders (NDDs) in individuals with 17q12 microdeletions (MIM
#614527) containing HNF1B.10,28-33 Although NDDs were considered
an exclusive feature of chromosome 17q12 microdeletion syndrome
(17q12DS), there are recent reports also in individuals with intragenic
HNF1B alterations.16,34-36
In this study, we report on a series of seven individuals with intragenic
HNF1B aberrations or 17q12DS and describe their renal and extra-renal
phenotypes prenatally and in childhood or adult life. By comparing our
findings of this cohort with reports from current literature, we discuss the
potential need to differentiate intragenic variants from 17q12DS in the
increasingly common setting of prenatally diagnosed kidney abnormalities.
This question is important not only for prenatal decision making but also
for postnatal management in affected individuals.
2 | SUBJECTS AND METHODS
2.1 | Individual 1 (I1)
A pregnant woman presented to our Department of Obstetrics and
Gynecology at gestational week 21 5/7 for sonographic examination.
An isolated bilateral renal cortical hyperechogenicity without kidney
enlargement was noted in the fetus. Amniotic fluid volume was nor-
mal, and amniocentesis was performed. Prenatal ultrasound at
32 weeks of gestation additionally revealed bilateral fetal pyelectasis.
The female individual I1 was born at gestational week 36 6/7 with
normal birth parameters. During the neonatal period, she manifested
a temporary respiratory adjustment disorder and feeding problems.
Postnatal kidney ultrasound at 3 months of age demonstrated a
regression of renal hyperechogenicity, bilateral renal cysts of varying
size, with the largest being 3 mm, an enlarged right kidney with a total
volume of 24 mL (97. P), renal pelvis dilatation grade I (8 mm) of the left
kidney, and bilateral megaureters of 2 mm. Sonographic examination of
liver and pancreas exhibited no structural anomalies. Blood glucose
level was slightly increased (110 mg/dL), indicating a predisposition to
diabetes. Urine albumin/creatinine ratio was 504 mg/g. Plasma magne-
sium and uric acid concentrations as well as liver transaminases were
normal. Additional postnatal findings included a minor atrial septal
defect. Ocular anomalies were not detected. At the time of last assess-
ment at age of 3 months, development and growth were in the normal
range. Renal sonographic examination of both parents did not reveal
any abnormalities (Figure 1C,D, Table 1, and Supplementary Note).
2.2 | Individuals 2 to 7 (I2-I7)
Clinical data of individuals I2 to I7 who presented with renal and/or
neurodevelopmental phenotypes at our genetic outpatient clinic and
at the Center for Rare Diseases Erlangen were retrospectively col-
lected for this study (Figure 1B). Detailed clinical descriptions are pro-
vided in Table 1 and Supplementary Note. Individual I7 was
previously described.37
2.2.1 | Genetic analyses including sequencing and
chromosomal microarray analysis
Details for next-generation sequencing (NGS)-based panel and Sanger
sequencing methods as well as chromosomal microarray analysis (CMA)
methods are described in Supplementary Note and Supplementary File
2. In brief, a custom panel was sequenced on an Illumina MiSeq,
processed bioinformatically as described38 and analyzed for variants in
four genes (PKD1, PKD2, PKHD1, and HNF1B) associated with polycys-
tic kidney disease. Sanger sequencing was used to confirm and validate
the segregation of identified variants, and long-range polymerase chain
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reaction (PCR) with subsequent Sanger sequencing was used to analyze
the duplicated regions of PKD1. Chromosomal microarray analysis data
were analyzed for CNVs ≥ 100 kb using Software ChAS and evaluated
against control databases (Supplementary Note).39
2.2.2 | Computational analyses of HNF1B variants
The clustering analysis of described HNF1B variants, the collection of
these variants from the literature together with computational ana-
lyses of all possible single amino acid (AA) deletions, and missense
substitutions as well as the protein structure analysis of the Gly239del
variant are described in the Supplementary Note, and all data are pro-
vided in Supplementary File 1. In brief, we collected an up-to-date list
of 217 intragenic HNF1B variants from 88 articles and public data-
bases, harmonized these according to the HGVS nomenclature, anno-
tated them with different computational scores, and evaluated their
pathogenicity according to the American College of Medical Genetics
and Genomics (ACMG) criteria. To analyze the spatial clustering, we
plotted the distribution of these variants across the linear protein rep-
resentation and estimated P values from empiric distributions of
drawing the observed number of missense variants in the respective
domains. Additionally, we used the published tertiary protein struc-
ture of HNF1B to analyze the potential effect and proximity to other
pathogenic variants of the herein identified c.715_717del, p.
(Gly239del) variant.
2.2.3 | Review of reported clinical features in
literature
To analyze the variable reporting of clinical symptoms in the literature,
we searched all 88 above-identified publications for 12 features asso-
ciated with HNF1B disorders. If the presence or absence of the
respective feature was mentioned, we scored the publication as 1, if
not as 0. Additionally, we categorized the publication type (review,
case reports [less than three cases], case series [more than equal to
three], and screening of HNF1B and/or other genes in larger cohorts),
the medical specialty (according to the journal topic or first/last
authors' affiliations), the HNF1B variant types analyzed (17q12del
and/or SNV/indel), and whether the publication described born indi-
viduals or fetal cases. The detailed results of this review are represen-
ted in Supplementary File 1 (sheet “publications_reviewed”) and
Figure S3 and summarized in Table 2.
F IGURE 1 A, Pictogram describing the prenatal diagnosis of hyperechogenic kidneys in individual I1 at gestational age 21 5/7 weeks
followed by amniocentesis and targeted panel sequencing, which identified the HNF1B variant c.715_717del. Postnatal segregation analysis in the
healthy parents confirmed de novo occurrence of the variant (pedigree). B, Pictogram summarizing the causes for referral of individuals I2 to I7
with 17q12 microdeletions. Affected organ systems are marked in dark green: brain, neurodevelopmental disorder; kidneys, renal dysfunction;
and a combination thereof both. C, Prenatal fetal sonography of individual I1 at gestational week 26 showing renal cortical hyperechogenicity
with reduced corticomedullary differentiation. D, Postnatal sonography of individual I1 at 5 months of age showing multiple small and one larger
cyst of the right kidney [Colour figure can be viewed at wileyonlinelibrary.com]
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3 | RESULTS
3.1 | Prenatal identification of a pathogenic in-
frame deletion in individual I1
Prenatal panel sequencing in individual I1 revealed a novel hetero-
zygous 3-bp deletion in exon 3 of HNF1B (NM_000458.3:
c.715_717del), resulting in an in-frame deletion of the highly con-
served AA glycine at position 239 (p.(Gly239del)) (Figure 2B). The
identified indel variant was not present in the Genome Aggregation
Database (gnomAD) and was computationally predicted (CADD,
MutationTaster) to be deleterious. A potential splice effect was not
detected (Human Splicing Finder, version 3.1). The c.715_717del
variant could not be identified in DNA from peripheral blood lym-
phocytes of both parents and thus likely arose de novo. Structural
modeling based on the crystal structure of the HNF1B protein
showed that the glycine at position 239 (Gly239) lies in an alpha-
helix motif of the homeodomain, which has DNA-binding function.
The deletion of Gly is predicted to disrupt two neighboring AAs
(Trp238 and Lys237) involved in binding to DNA (Figure 3). Two
missense variants (c.715G>C, p.(Gly239Arg)40; and c.716G>A, p.-
(Gly239Glu)41) affecting the same AA were reported in a boy with
bilateral renal cysts, kidney failure, and diabetes in childhood and in
a girl with MODY, renal cysts in the right kidney, agenesis of left
kidney, and pancreas atrophy, respectively. Furthermore, a variant
affecting the neighboring residue Trp238 (c.712T>C, p.(Trp238Arg))
was described as pathogenic (Figure 3).9 On the basis of the ACMG
criteria42 (de novo occurrence, no inclusion in population databases,
previously described variant at the same position, affected highly
conserved AA, and computationally indicated pathogenicity), we
classified the identified variant as pathogenic (class 5).
3.2 | 17q12 microdeletions in individuals I2 to I7
Postnatal high-resolution CMA in individuals I2 to I7 revealed
17q12 microdeletions of variable sizes ranging from 1.42 Mb in I5
to 1 80 Mb in I6 (Figure 2A). De novo occurrence was confirmed in
all cases apart from individual I3, where the deletion was excluded
in the mother, but paternal DNA was not available (see also Table 1
and Supplementary Note).
3.3 | Clinical features of the affected individuals
Prenatal renal anomalies such as hyperechogenic kidneys were only
identified in individual I1 with the in-frame deletion in HNF1B
(Figure 1C), whereas information on prenatal kidney examination of
the remaining individuals was not available. Postnatally, 4/7 individ-
uals exhibited renal cysts. Individual I1 was diagnosed with multiple
renal cysts in early infancy (Figure 1D), I3 and I5 in puberty, and I6
in adulthood. Other renal abnormalities included kidney enlarge-
ment, renal pelvis dilation, and bilateral megaureter in individual I1
as well as right kidney aplasia and left kidney hypoplasia in individ-
ual I7. Recurrent urinary tract or kidney infections from childhoodT
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onward were reported in individuals I6 and I7. Individuals I5 and I7
developed stage II and end-stage renal disease in their late teens, and
I6 developed end-stage renal disease after the age of 26. In individuals
I2 and I4, no renal manifestations were reported at last follow-up, at
the age of 8 years 8 months and 12 years, respectively.
Two individuals had diabetes, both diagnosed in puberty (I5 and
I6). I1 showed slightly increased blood glucose levels at 3 months of
age. Other extra-renal manifestations included strabism (I4, I5, and I7),
elevated liver enzyme levels (I4 and I6), liver cysts and primary biliary
cirrhosis (I6), hyperuricemia (I5), short stature (I4), uterus aplasia and
ovarian cysts (I7), and cardiac anomalies (I1, I2, and I7).
The most prominent extra-renal phenotypes in individuals with
17q12DS were NDDs and behavioral problems (Figure 1B). Individual
I2 exhibited learning difficulties, I3 mild intellectual disability and
Asperger syndrome, and I4 a low-normal IQ with learning and concen-
tration difficulties. Behavioral problems varied from oppositional
behavior (I2) and hyperactivity and restlessness (I3) to autistic-like
behavior (I4). Motor milestones were delayed in I4 and I6. Individual
I6 had a single seizure attack in adulthood. Finally, magnetic reso-
nance imaging (MRI) showed enlarged brain ventricles in individual I4
(Table 1 and Supplementary Note).
3.4 | Reviewed intragenic variants and clustering in
protein domains
We retrieved a total of 217 intragenic HNF1B variants from data-
bases, 88 published articles, and this report (I1) (Supplementary File
1). Only 46/216 variants (21.3%; excluding the variant in individual I1)
were deposited in public databases as of 2018-12-02. After manual
review, 192 of them could be classified as ACMG class 4 (likely patho-
genic; n = 57) or 5 (pathogenic; n = 135). For four variants described
in the literature, there was enough evidence to classify them as
ACMG class 2 (likely benign), while for 21 variants, only insufficient
information was available, and they were classified as ACMG class
3 (uncertain significance). The majority of (likely) pathogenic variants
in HNF1B are truncating (59.4%; 114/194), whereas missense vari-
ants, clustering in important protein domains, constitute the second
largest group (39.1%; 75/194) (Figure 2B and Supplementary File 1).
Besides the c.715_717del variant in individual I1, two larger indels
of 30 bp (c.1118_1147del) and 75 bp (c.410_484del) are annotated as
in-frame variants deleting 10 (p.(Ala373_Gln383delinsGlu)) or 25 (p.
(Arg137_Lys161del)) AAs, respectively. While these two variants are
annotated as “disruptive” (Figure 2B, marked in purple below protein
scheme) because they ablate multiple AAs that likely disrupt the pro-
tein structure, the herein identified in-frame deletion of glycine at
position 239 (p.(Gly239del)) is annotated as “conservative” (Figure 2B,
marked in purple above protein scheme). Besides affecting an AA
position previously described as mutated in patients with HNF1B-
associated disease, the deletion is located within the HNF1B
homeodomain, which mediates DNA binding.
The HNF1B homeodomain and the second half of the N-terminal
domain (“HNF-1_N”) host the two mutational hot spots for missense
variants, while likely gene disruptive variants are dispersed throughout
the protein (Figure 2B, middle panel). The possible missense variants
in these two domains additionally have significantly higher CADD
scores when compared with those of the C-terminal domain (“HNF-
1B_C”) or nondomain regions of the HNF1B protein (Figure 2B, lower
panel; and Figure S1).
4 | DISCUSSION
Improved sonographic technologies increasingly enable the identifica-
tion of fetal hyperechogenic and/or cystic kidneys. Nevertheless,
identifying the underlying cause and specifying prognosis remain
TABLE 2 Reported prevalence for 12 clinical features associated with 17q12DS or HNF1B variants and frequency of these phenotypes as
described in 82 published articles with clinical data on born individuals
Phenotype HPO Reporteda Prevalence in Literature
Abnormality of the kidney HP: 0000077 76/82 (92.7%) 61%-91%
Neurodevelopmental delay HP: 0012758 10/82 (12.2%) 30%-89%: 17q12 deletions
11%: HNF1B variants
Diabetes mellitus HP: 0000819 76/82 (92.7%) 9%-82%
Abnormality of the genital system HP: 0000078 39/82 (47.6%) 18%-80%
Elevated hepatic transaminase HP: 0002910 35/82 (42.7%) 12.5%-84%
Abnormality of the liver HP: 0410042 24/82 (29.3%) 20%-32%
Abnormality of the pancreas HP: 0001732 33/82 (40.2%) 6%-54%
Abnormality of brain morphology HP: 0012443 3/82 (3.7%) 4%-50%
Short stature HP: 0004322 16/82 (19.5%) 4%
Abnormality of the eye HP: 0000478 7/82 (8.5%) 40%-44%
Abnormal magnesium concentration HP: 0004921 21/82 (25.6%) 25%-75%
Hyperuricemia HP: 0002149 31/82 (37.8%) <10-67%
Abbreviation: HPO, Human Phenotype Ontology terms.
aFraction of publications mentioning the respective feature (eg, absence or presence count as mentioned).
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F IGURE 2 A, 17q12 microdeletions on chromosome 17q12 (red box) identified in individuals I2 to I7 (light red labeled bars) with location of
genes typically affected by these copy number variants (CNVs) (see also Supplementary File 1, sheet “CNV_genes”). Dark red bars indicate the
minimal 17q12 microdeletion and the variability observed in 33 cases from the DECIPHER database, respectively. The location of HNF1B gene
within the CNV is highlighted (blue box), and the exon structure for transcript NM_000458.3 is indicated above the blue box. Location of the
c.715_717del variant in exon 3 is indicated by the purple circle. B, Top panel: linear schematic representation of the HNF1B protein (based on
NP_000449.1) with domains (limits indicated by ticks below the x-axis) and localization of all described (likely) pathogenic variants (length of the
segments corresponds to the variants CADD score). The small red segments on the homeodomain represent amino acid (AA) residues directly
involved in DNA binding or with specific DNA base contacts. Dim, N-terminal dimerization domain specific for the formation of homodimers or
heterodimers with HNF1A; HNF-1_N, N-terminal domain involved in DNA binding; homeodomain, DNA-binding domain; HNF-1B_C, C-terminal
transactivation domain which mediates the transcription and recruitment of coactivators.57 The blue circles indicate all missense variants (above
the schematic) and the red all truncating variants (below the schematic) described in the literature and databases. The in-frame indel
c.715_717del, p.(Gly239del) (above the schematic and presented as larger circle) and two in-frame deletions of whole exons (below the
schematic) are presented in purple. Middle panel: density plot of truncating (red) and missense (blue) variants reported. Missense variants show a
maximal density at AA 154 in the HNF-1_N domain and a local maximum at AA 280 in the homeodomain. Bottom panel: generalized linear model
of the CADD score for all possible missense variants (circles) in HNF1B [Colour figure can be viewed at wileyonlinelibrary.com]
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challenging. The recurrent 17q12 microdeletion encompassing HNF1B
constitutes a frequent differential diagnosis for fetal renal anomalies
with variable postnatal consequences ranging from isolated renal to
more complex, syndromic manifestations.11,15,19,22 The emerging role
of HNF1B intragenic variants for prenatally detected renal and extra-
renal phenotypes has only recently been recognized.11
Panel sequencing of common genetic causes for prenatal-onset
kidney anomalies in individual I1 with hyperechogenic kidneys in fetal
ultrasound identified the novel in-frame single AA deletion
c.715_717del, p.(Gly239del) in HNF1B. This is the first report of an in-
frame HNF1B variant leading to a renal phenotype resembling that of
previously described HNF1B cases. One of the main questions in this
prenatal situation was further prognosis. Because of the variable pre-
sentation of HNF1B aberrations with renal and extra-renal plus possi-
ble neurodevelopmental aspects, this is particularly challenging.
Currently, prenatal prognosis and decision making regarding TOP
depend mainly on clinical presentation including oligohydramnios and
detectable congenital anomalies. However, other issues to consider
during prenatal genetic counseling without severe complications are
frequency and severity of the various postnatal manifestations.
In this regard, the association of 17q12DS with a wide spectrum
of NDDs in 30% to 89% individuals is of particular importance
(Table 2).10,29-33,43 In our cohort, three individuals diagnosed with
17q12DS (I2-I4) presented primarily with psychomotor deficits and
behavior anomalies, and two (I4 and I6) required therapy for delayed
motor development in childhood. Although very young, individual I1
with the intragenic HNF1B variant did not show any signs of develop-
mental delay. Clissold and colleagues provided evidence for associa-
tion of NDDs exclusively with 17q12 microdeletions but not with
HNF1B intragenic variants.30 The predominant hypothesis for the
neurodevelopmental phenotypes was haploinsufficiency of other
genes encompassed by the deletion.28,29,31,33,43 Until recently, only
single cases of NDDs in carriers of intragenic HNF1B variants had
been reported.16,34,36 However, a recent study described NDDs in
(6/54) 11% of individuals with MODY harboring HNF1B intragenic
alterations; this frequency was significantly higher than in cases who
had another cause of diabetes and not significantly different from
17q12DS cases (17.0%; 9/53).35 This study only excluded CNVs and
fragile X syndrome in individuals with NDDs without further applica-
tion of exome sequencing. This leaves the possibility of a second,
independent variant causing a blended phenotype, as has been shown
for 4.9% of the cases in a large cohort of individuals receiving exome
sequencing for different diseases.44 After the report of NDDs in car-
riers of intragenic variants, HNF1B has been included in curated gene
lists for NDDs (SysID45; PanelApp “Intellectual disability Version
2.595”), without experimental data supporting the clinical observa-
tions. Contradicting this association, no intragenic HNF1B variant has
been observed in several thousand individuals of large cohorts with
autism46 or developmental disorders.47 Thus, it still remains unclear
whether there is a causal link of HNF1B loss-of-function to NDDs.
The difficulty of quantifying the NDD risk in both groups with HNF1B
deletions and intragenic alterations is a primary cause of parental
dilemma during prenatal decision making. Further complicating esti-
mation, published patient cohorts and case reports are often limited
to describing only a subset of HNF1B-associated clinical traits, as
shown by our evaluation for 12 HNF1B-associated phenotypes men-
tioned in 82 published studies reporting phenotype data on born indi-
viduals (Table 2, Figure S3, and Supplementary File 1). New studies
should follow a minimal, standardized clinical reporting scheme
(Table 2) to enable fast systematic reviews and facilitate future esti-
mation of prevalence for important symptoms like NDDs. Next to this
clinical evaluation, behavioral analysis experiments of HNF1B knock-
out animal models may provide further insight of the involvement of
this gene in neurodevelopment.
Postnatally, the presence of accompanying organ anomalies is
important to guide appropriate management and surveillance. In the
present study, 5/7 (71.4%) individuals with either HFN1B intragenic
variant or larger deletion had renal manifestations, in agreement with
the previously reported 61% to 91% prevalence in HNF1B cases
(Table 2).9,48 Absence of renal disease in individuals I2 and I4 may be
attributed to a milder renal phenotype overshadowed by developmen-
tal deficits33 or to their young age. Even though renal anomalies were
only prenatally reported in individual I1 in our cohort, we cannot
F IGURE 3 Crystal structure of HNF1B (grey) monomer bound to
the DNA double helix (green) based on PDB 2H8R.57 The amino acid
(AA) residue Gly239 mutated in individual I1 is shown in sphere
representation (red). The neighboring residues Trp238 (cyan) and
Lys237 (blue) are annotated as having a “specific DNA base contact
[s]” or being involved in “DNA binding,” respectively (based on NCBI
NP_000449.1). Additionally, the variant c.712T>C, p.(Trp238Arg), has
been reported as pathogenic.9 The typical alpha-helix breaker glycine
at position 239 is located at the end of an alpha-helix motif
(residues 240-252; purple), and its deletion (I1 described herein) or
substitution40,41 likely disrupts the conformation and positioning of
the AAs Lys237 and Trp238 required for DNA binding of the HNF1B
transcription factor. The dashed box shows a close-up view of the
affected region and the distances between the AA residues and the
DNA double helix in angstrom [Colour figure can be viewed at
wileyonlinelibrary.com]
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exclude that they were present but not detected or were not tested
at all in the remaining cases with renal manifestations identified after
birth (I3 and I5-I7). In the literature, the severity of prenatal renal phe-
notypes is not correlated with the type of HNF1B aberrations.11 Nota-
bly, HNF1B intragenic variants progressively result in more severe
renal function impairment and poorer renal prognosis postnatally than
17q12 deletions.9,30 Accordingly, renal cysts were diagnosed in indi-
vidual I1 directly after birth, whereas 4/6 (66,7%) 17q12DS individ-
uals showed renal abnormalities later in infancy, puberty, or early
adult life. Regardless of the initial clinical indication for testing, identi-
fication of 17q12 deletions should always be accompanied by regular
blood and urine tests and sonographic kidney evaluation.
The frequency of diabetes in individuals with HNF1B-related clini-
cal phenotypes is highly variable, ranging from 9% to 82% with a
mean age of diagnosis at 24 years, but neonatal onset is also possible
(Table 2).9,12,48,49 Consistently, two 17q12DS individuals (I5 and I6)
were diagnosed with diabetes in puberty, whereas individual I1
showed slightly increased levels of blood glucose in early infancy,
which could be considered as a first indication of the presence of dia-
betes. Further subsequent glucose measurements at a later age were
though not available. The remaining individuals did not exhibit diabe-
tes to date, yet at least for individuals I2 to I4, this may relate to their
young age. The severity of diabetes was shown to be similar in both
carriers of truncating and missense variants. Dubois-Laforgue et al
reported a lower body mass index (BMI) and more severe diabetes
observed at diagnosis in 17q12DS as compared with intragenic vari-
ant cases.9 In addition to annual glycated hemoglobin (HbA1c) and
glucose level measurements, both carriers of 17q12DS and intragenic
HNF1B variants should be trained to self-monitor diabetes symptoms
in order to enable early diagnosis and avoid complications.
Other noteworthy clinical features of the herein described individ-
uals are short stature in individual I4, uterus aplasia in individual I7,
and strabism in individuals I4, I5, and I7. Gonadotrophin treatment
increased the predicted final adult height of individual I4 for about
10 cm. Yet reports on growth restriction in individuals with
17q12DS29 or HNF1B intragenic variants36 are rare, and the efficacy
of growth hormone treatment in these cases needs elucidation.
Uterus aplasia is within the HNF1B-associated spectrum, with intra-
genic variants and whole deletions reported in 18% to 50% of women
with uterine and renal anomalies.9,24 Thus, obstetric evaluation
already at young age is required. Finally, detailed ophthalmic examina-
tion is warranted, since in 40% to 44% of HNF1B aberration carriers,
strabism and other ocular anomalies were reported (Table 2).10
The reasons for the phenotypic variability within the two groups
of individuals with HNF1B intragenic alterations and whole deletions,
as well as between these groups, currently remain unclear. The clinical
diversity observed within the 17q12DS carriers could be attributed to
the incomplete penetrance and variable expressivity of this CNV, simi-
lar to other recurrent microdeletions.50 A variable quantitative impact
of the 17q12 microdeletion, which is difficult to be ascertained from
the small cohorts examined, could, for instance, justify the presence
or absence of NDDs in affected individuals.50,51 Regarding clinical dif-
ferences within the intragenic variants group, different
pathomechanisms, especially for the missense variants, constitute a
possible hypothesis. Indeed, a dominant negative effect, allowing a
residual function of the HNF1B protein rather than haploinsufficiency,
has been discussed for some variants.52 The differential phenotypic
presentation between the 17q12DS and intragenic aberration cohorts
could be explained by the concurrent loss of other genes
encompassed in the microdeletion and interruption of interaction cas-
cades with transcription factors or other regulatory elements. For
instance, haploinsufficiency of two other genes (ACACA, MIM
*200350; and ZNHIT3, MIM *604500) was indicated as the cause of
the leaner figure and more severe diabetes at onset in 17q12DS
cases.9 This hypothesis was also suspected for the presence of NDDs
in individuals with microdeletions.33,43 From the remaining 37 pro-
tein-coding genes encompassed in the deletion, seven have been
implicated with NDDs, of which only PCGF2 (MIM *600346) with
dominant53 and PIGW (MIM *610275) with recessive inheritance54
have a confirmed association, whereas the rest are considered candi-
date genes. Consequently, PCGF2 is the most notable candidate; how-
ever, it does not seem to be intolerant to heterozygous loss-of-
function and missense variants (pLI = 0.85, Z score = 1.21), and all
described PCGF2 carriers have the same recurrent missense variant
with dominant negative effect (Supplementary File 1).53 In agreement,
in the largest study attempting a genotype/phenotype correlation in
75 individuals with HNF1B alterations, no clear phenotypic differences
regarding renal disease were identified between 17q12DS and intra-
genic variant carriers.11 Therefore, the possibility remains that HNF1B
is indeed the critical gene for all associated phenotypes and that most
of the variability is caused by additionally modifying genetic and
developmental factors.
To date, only one recent study applying exome sequencing for
CAKUT cases prenatally detected a HNF1B frameshift variant.55 Like-
wise, the herein reported prenatal identification of an intragenic
HNF1B variant in individual I1 is likely a consequence of increased
availability and demand for such NGS-based techniques. Because of
the known high frequency of intragenic HNF1B variants in fetal
autopsy cases8,19,27,56 or in postnatally diagnosed children with renal
diseases,11,15,22,30,34,36 HNF1B mutation screening should be an inte-
gral part of prenatal diagnosis for hyperechogenic/multicystic kidneys.
Customized targeted panels capturing multiple cystic kidney disease-
related genes, like the one used herein, have several favorable fea-
tures for the prenatal setting: high coverage, short turnaround times,
and compatibility with small benchtop sequencing machines. Clinical
exome sequencing (covers approximately 5000 to 7000 disease
genes) is currently a reasonable compromise, although it requires
more time and is less accessible. Regardless, NGS should be rec-
ommended concurrently with CMA for rapid prenatal diagnosis in
fetuses with hyperechogenic or cystic kidneys. However, the applica-
tion of next-generation methods will consequently result in the
increased identification of pathogenic variants and variants of
unknown significance (VUS). To facilitate fast and effective assess-
ments, all identified variants should be systematically classified and
deposited in appropriate databases, as performed in this study for all
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described in the literature so far (Supplementary Note and Supple-
mentary File 1).
In conclusion, similar to previous studies, our study indicated no
differences in the prenatal renal phenotypic spectrum between intra-
genic HNF1B aberrations and 17q12DS, and a wide range of postnatal
renal and extra-renal abnormalities for both. The most prominent
postnatal phenotypic differences, potentially affecting prenatal deci-
sion making, are a more severe progress of renal impairment in indi-
viduals with intragenic HNF1B variants and the increased NDD risk,
which is a confirmed feature in 17q12DS and suspected in HNF1B
intragenic variant carriers. Incomplete references to the overall clinical
presentation of the affected individuals in the published reports and
previous classifications of identified variants not following current
recommendations of a standardized five-tier system add to the diffi-
culty of risk estimation. We, therefore, systematically collected
HNF1B-related clinical traits, revised and harmonized all intragenic
variants from 88 articles, and proposed a minimal reporting scheme
for HNF1B-associated disease (Table 2). Building on these efforts,
future studies using a standardized ascertainment of phenotype/
genotype information will improve our understanding and characteri-
zation of HNF1B-associated disorders and enable the optimization of
genetic counseling.
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